L'Oreal to buy three skincare brands from Valeant for $1.3 billion

Valeant Pharmaceutical

Beta factor of the stock stands at 1.77.

"With the slower than forecasted recovery in our dermatology business and underperformance of other select businesses, we have limited headroom in complying with the 2.5x secured leverage ratio maintenance covenant, the filing said". The analyst notes that CereVe was one of the key growth drivers for the company and yielded more than 20% growth in the past two years.

11/14/2016 - Valeant Pharmaceuticals International, Inc. had its "market perform" rating reiterated by analysts at BMO Capital Markets.

Over the period of 6 months, Insider Purchases show a total of 6 transaction in which 30775 shares were traded. Inc. purchased a new stake in Valeant Pharmaceuticals International during the third quarter valued at approximately $367,000. Inc. raised its position in Valeant Pharmaceuticals International by 1.4% in the second quarter. The company has a market cap of $5.70B. Expected growth of Valeant Pharmaceuticals International, Inc.

U.S. military to monitor development of new North Korean missile
Kim Jong-Un said during his New Year speech that his country is on the verge of testing an intercontinental ballistic missile. North Korea deactivated the Yongbyon reactor in 2007 under an aid-for-disarmament deal.


The share price of the company (NYSE:VRX) was up +0.39%, with a high of 15.65 during the day and the volume of Valeant Pharmaceuticals International, Inc. shares traded was 9528818. The firm has Profit Margin of positive 4.30%. The company earned $2.48 billion during the quarter, compared to the consensus estimate of $2.49 billion. The company had Year Ago Sales of 2.79 Billion. If you are viewing this piece on another site, it was copied illegally and reposted in violation of United States and worldwide copyright law.

Evecore ISI analyst Umer Raffat considered in on subsequent 3 press-releases from yesterday which he mentioned "all read good".

"The valuation is pretty high; this is a decent price" that Valeant is getting for the skin-care brands, said Rudi van Den Eynde, who helps oversee about US$1 billion in assets at Candriam Investors Group, including L'Oreal shares. Deutsche Bank AG started coverage on Valeant Pharmaceuticals International in a report on Tuesday, September 20th. And based on how strong these deals were for the company, perhaps it has more negotiating power than we originally thought. Also, Director Pershing Square Capital Manage sold 3,476,690 shares of the stock in a transaction on Monday, December 12th. The company reported its last quarter on Sep 16. BTIG maintained a Neutral rating on. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have given a buy rating to the stock.

Price Target plays a critical role when it comes to the Analysis of a Stock. "We aim to introduce one of the most advanced medical technologies and treatments to China and also other major Asian markets, and make Sanpower Group a China's leading enterprise in cellular immunotherapy", said Yuan Yafei, Chairman of Sanpower Group.

Related news: